Index

A
ACC. *See* Adrenal cortical carcinoma (ACC)
ACTH. *See* Adrenocorticotropic hormone (ACTH)
Acute thyroiditis, 14
Adenomatoid tumor
  asymptomatic and identified, 204
  cortical cells and focal lipomatous metaplasia, 205
  spaces, small glandular, 205
Adrenal cortical carcinoma (ACC)
  aldosteronism, 168
  alveolar pattern, 169
  cellular and nuclear pleomorphism, 167
  cystic degeneration, 171
  cytotoxic chemotherapy, 173
  description, 173
  eosinophilic cells, 167, 168
  eosinophilic cytoplasm, 170, 172, 179, 180
  feminizing/virilizing tumors, 165
  histologic features, 173
  insulin-like growth factor 2, 173
  keratin, 181
  lipid-rich adrenal cortical adenoma cells, 168
  lipofuscin, 171
  lipomatous/myelolipomatous, 167
  lymphoma, 177
  mitotic figures, 175
  multivariate analysis, 165
  myxoid change
    and epithelioid cells, 170
    and spindle cells, 170
  necrosis, 175
  nuclear-to-cytoplasmic ratios
    and cellular monotony, 174
    monotonous cells, 176
    mucin, 178
    pleomorphism, 176
  oncocytic adenomas, 171
  pale lipid-rich cell, 166
  pale-staining cells, 167
  pediatric tumors, 173
  polymorphous cells, 176
  primary hyperaldosteronism, 168
  pseudoglandular growth pattern, 169
  pseudoglandular pattern, 177
  punctate microscopic foci, 175
  small cell cytomorphology, 178
  spindle cell change, 179
  spironolactone bodies, 169
  subclinical Cushing syndrome, 166
  trabecular growth pattern, 176
  tumor behavior, 170
  tumor size and weight, 174
  unilateral tumors, 165
Adrenal cortical hyperplasia
  autosomal dominant disorder, 159
  description, 159
  diffuse
    ectopic ACTH production, 160
    enlargement, 161
    pancreatic neuroendocrine tumor, 160
    secondary hyperplasia, 160
    zona fasciculata, 160
  nodular
    definition, 161
    endocrine atypia, 162
    macro- and micronodules, 161, 162
  PPNAD (*see* Primary pigmented nodular adrenocortical disease (PPNAD))
  PRKAR1A gene, 159
Adrenal cysts
  CD31-immunostained sample, 156
  endothelial-lined adrenal cysts, 156
  fibrous-walled adrenal pseudocyst, 156
  pheochromocytomas, 155
  pseudocysts, 155, 156
  vague symptoms, 155
Adrenal gland
  abnormalities and pathogenic processes, 147
  adipocytes and lymphocytes, 151
  central adrenal vein, 150
  chromaffin cells, 150
  encapsulated cortical extrusions, 151
  formalin, 148
  heterotopia (*see* Heterotopia)
  medullary hyperplasia, 147
  pheochromocytomas, 147
  right and left adrenal glands, 148
  scattered adipocyte, 150
  zona
    fasciculata, 149
    glomerulosa, 148
    reticularis, 149
Adrenal gland tumors
  adenomatoid, 204–205
  angiosarcoma, 202
  leiomyosarcoma, 203
  teratoma, 204
Adrenal medullary hyperplasia
  description, 187
  MEN2A, MEN2B and cystic fibrosis, 188
  pheochromocytoma, 188
  trabecular growth pattern, 188

L.A. Erickson, *Atlas of Endocrine Pathology*, Atlas of Anatomic Pathology,
DOI 10.1007/978-1-4939-0443-3, © Springer Science+Business Media New York 2014

Adrenal myelolipoma
adjacent adrenal cortical tissue, 184
bilateral, 183
cortical tissue, 184
description, 183
hematopoietic elements, 184
hypersecretion, 183
trilineage hematopoietic cells, 185
yellow adipose tissue, 184
Adrenal tumors, metastatic
breast cancer, 209
cortical, 207
medullary, 207
melanoma, 208
neuroendocrine, 207
primary, 207
renal cell carcinoma, 208
Adrenocorticotropic hormone (ACTH)
in congenital adrenal hyperplasia, 159
cortical hyperplasia, 159
neuroendocrine tumor, 160
Amiodarone thyroid, 5–6
Amyloid goiter, 25, 28–29
Anaplastic thyroid carcinoma
adjacent structures, invasion, 72
atypical spindle cells, 73
composition, 71, 73
distant metastases, 71
hemorrhage and necrosis areas, 72
Hurthle cell carcinoma, dedifferentiation, 74
papillary thyroid carcinoma (PTC), 74–75
Rhabdoid features, 74
Riedel (fibrous) thyroiditis, 71, 73
TTF1, 71
vascular invasion, 72
Angiosarcoma, 92, 202
Atypical parathyroid adenoma
composition, 128
hypercellular and fibrosis, 128
indolent behavior, 128
irregular growth and fibrous bands, 129
Ki67 labeling index, 129
monotonous growth, 129
parathyroid carcinoma, 128

B

Breast cancer, 209
Brown tumor of bone, 113

C

Calcifications, 81
Carcinoembryonic antigen (CEA), 84
Carcinoma showing thymus-like differentiation (CASTLE), 94–95
CASTLE. *See* Carcinoma showing thymus-like differentiation (CASTLE)
C cells, tumors
hyperplasia, 78
medullary thyroid microcarcinoma, 78–79
MTC (*see* Medullary thyroid carcinoma (MTC))
CEA. *See* Carcinoembryonic antigen (CEA)
Chief cells, parathyroid histology, 103–104
Classic PTC
cervical and ipsilateral lymph nodes, 35
characteristic cytologic features, 33
colloid, 34
cystic-appearing lymph node metastasis, 36
growth patterns, 34
intranuclear holes, 34
invasive, 32
low-power photomicrograph, 35
multiple ill-defined firm masses, 32
“Orphan Annie” nuclei, 32
papillae with fibrovascular cores and cystic change, 32, 33
prominent papillae with fibrovascular cores, 32, 33
psammoma bodies, 33
Columnar variant of PTC, 47
Composite pheochromocytoma
composition, 194
ganglioneuroma, 194
Cowden syndrome, 25
Cribriform-morular variant of PTC
aberrant nuclear and cytoplasmic staining, β-catenin, 41
arches and anastomosing bars, 40
autosomal dominant syndrome, 40
morules, 41
nuclear staining, TTF1, 41
spindle/oval tumor cells, 41

D

de Quervain thyroiditis. *See* Granulomatous (de Quervain) thyroiditis
Diffuse hyperplasia. *See* Graves disease
Diffuse sclerosing variant of PTC, 43
Dyshormonogenetic goiter, 27–28

F

Familial isolated hyperparathyroidism (FIH), 131
Fibrous (Riedel) thyroiditis, 13, 16, 71, 73
FIH. *See* Familial isolated hyperparathyroidism (FIH)
Focal lymphocytic thyroiditis, 13, 18
Follicular adenoma
adipocytes, 57
clear cell change, 56, 57
degenerative feature and hyalinization, 59
description, 55
extensive signet ring cell change, 58
immunoperoxidase markers, 56
medium-power view, 59
metaplastic bone/ossification, 59
microfollicular and macrofollicular architectural pattern, 56
mucin, 57
prominent spindle cell change, 58
signet ring cell change, 58
thyroid, 56
Follicular carcinoma
capsular invasion, 60
clear cell change, 61, 62
description, 60
mushroom-like area, 60
signet ring cell change, 62
spindle cell change, 62
thrombus, 61
vascular invasion, 60, 61
Follicular thyroid neoplasms
adenomas (*see* Follicular adenoma)
carcinomas (*see* Follicular carcinoma)
cytologic specimens, 55

histologic patterns, 55
malignancy, 55
tumors with extensive vascular invasion, 55
Follicular variant of papillary thyroid carcinoma (FVPTC)
characteristic features, 38
classic PTC, 37, 39
cumulative diagnosis, 37
elongated follicles, 38
encapsulated tumors, 37
HBME-1 immunostain, 40
low-power photomicrograph, 39
numerous patterns, 38
photomicrograph shows, 38
thyroid parenchyma, 39

G
Ganglioneuroma
adrenal gland, 198
needle core biopsy, 198
recognizable tumor, 197
spindled Schwann cells, 199
stroma-rich, 198
Granulomatous (de Quervain) thyroiditis
multinucleated giant cells, 15
noncaseating granulomas, 15
patchy areas, neutrophils and microabscesses, 14
patients, 13, 14
Graves disease
complications, 21
cut section, 22
diffuse hyperplasia, 23
diffusely enlarged thyroid, 22
follicular epithelium, 24
hyperthyroidism, 21
low-power photomicrograph, 22
papillae, 22, 23
patients treatment with iodine, 24
thyroid carcinomas, 21
thyroid parenchyma, 22

H
Hashimoto thyroiditis
fibrous variant, 18
prominent lymphoid follicles, 17
solid cell nests, 18
thyroid, 13
H&E. *See* Hematoxylin and eosin (H&E)
Hematoxylin and eosin (H&E), 1, 4
Heterotopia
adipocytes and foci, lymphocytes, 152
cortical nodule, 152
embryologic path, 152
subcapsular space, 152
Hobnail variant of PTC, 48
HP-JT. *See* Hyperparathyroidism–jaw tumor syndrome (HP-JT)
Hurthle cell adenoma, 63, 64
Hurthle cell carcinoma, 65
Hurthle cell thyroid neoplasms, 63–65
Hyalinizing trabecular tumor
Carney's group, 51
description, 51
encapsulation and separation, 52
extracellular eosinophilic hyaline fibrosis, 52
prominent eosinophilic intranuclear inclusions, 52
RET/PTC rearrangements, 51
tumor cells, 52
Hyperparathyroidism–jaw tumor syndrome (HP-JT), 131

L
Langerhans cell histiocytosis, 91
Leiomyosarcoma, 203
Lipoadenomatous hyperplasia, 114
Lipohyperplasia, 109
Low-grade fibromyxoid sarcoma, 93
Lymphoma, 90

M
Medullary thyroid carcinoma (MTC)
acinar growth pattern, 82
amyloid, 79
calcifications, 81
calcitonin, 83
CEA, 84
composition, 81
epithelioid cells, 80
growth patterns, 80
intranuclear pink holes, 80
neuroendocrine markers, 83
oxyphilic, 82
papillary architectural pattern, 83
recognization, 82
solid growth, necrosis, 81
spindle cells, 80
syndromic, 79
TTF1, 83, 84
Metastases to parathyroid
carcinoma, 144
medullary thyroid carcinoma, 144
primary thyroid tumors, 143
thyroid tumors, 144
Metastases to thyroid
breast cancer metastatic, 100
melanoma metastatic, 101
primary tumors, 99
renal cell carcinoma metastatic, 100
resection, 99
Minocycline thyroid, 5–6
MTC. *See* Medullary thyroid carcinoma (MTC)
Multinodular goiter, 26–27
Multiple endocrine neoplasia (MEN) types 1 and 2A, 109

N
Nephrolithiasis, 121
Neuroblastoma
children, 197
classification, 197, 199
ganglion and Schwann cells, 197
malignant, 197
nests, 200
primordial neural crest cells, 199
sporadic, 197

Normal thyroid
central lumen containing colloid, 3
chromogranin immunostain, 4
cut section, 2
fat cells, 4
follicles, 3
gross image, 2
immunopositivity, TTF1, 3
thyroglobulin, immunopositivity, 3

O
Oncocytic/Hurthle cell, 44
Oxyphilic cells, 104

P
Palpation thyroiditis, 7
Papillary thyroid carcinoma (PTC)
BRAF mutations, 31
classic (*see* Classic PTC)
columnar variant, 47
cribriform-morular variant (*see* Cribriform-morular variant of PTC)
diffuse sclerosing variant, 43
and FVPTC (*see* Follicular variant of papillary thyroid carcinoma (FVPTC))
histologic variants, 31
hobnail variant, 48
microcarcinoma, 36, 37
oxyphilic variant, 44
patients, 31
radioactive iodine, 31
solid variant, 45
tall cell variant, 46
warthin-like variant, 42
Papillary thyroid microcarcinoma
benign thyroid disease, 37
gross photograph, 36
Paraganglioma, 96
Parathyroid adenoma
atypical parathyroid adenoma, 128–129
chief cell
composition, 123
cystic change, 124
degenerative edema, 123
diffuse cellularity, 122
edematous change, 123
features, 122
fibrous connective tissue capsule, 122
glandular growth, 124
hyalinization and metaplastic bone, 123
large dilated follicular-like spaces, 125
parenchyma cells and adipocytes, 122
signet ring cell change, 124
spindle cell change, 125
stromal fat, 123
clear cell, 126
molecular basis, 121
nephrolithiasis, 121
oxyphil cell, 125–126
parathyroid lipoadenoma, 127
screening calcium, 121
Parathyroid carcinoma
clear cell, 137
dilated follicular structures, 135
features, 132
FIH, 131
glandular growth pattern, 135
hemosiderin deposition, 134
HRPT2 tumor suppressor gene, 131
hyperplasia and, 133
intrathyroidal, 133
invasive growth, 132
monotonous growth pattern, 134
multiple mitotic figures, 134
nuclear atypia and mitotic activity, 137
oxyphilic, 135–136
palisading, 136–137
perithyroidal soft tissue, 132
postoperative radiation, 131
prognostic factors, 131
PTH, 131
skeletal muscle, neck, 132–133
trabecular growth pattern, 136
vascular thrombus, 133
Parathyroid histology
chief cells, 103–104
clear cytoplasm and pyknotic nuclei, 105
cysts and inflammation, 103, 105–106
normal, 104
in older patients, 105
oxyphilic cells, 104
parathyroiditis, 106–107
Parathyroid hormone (PTH), 109, 131
Parathyroid hyperplasia
asymmetric enlargement, 109
brown tumor of bone, 113
lipoadenomatous hyperplasia, 114
lipohyperplasia, 109
multiple endocrine neoplasia (MEN) types 1 and 2A, 109
primary
adipocytes, 110
chief and clear cells, 111
glandular growth pattern, 112
nodular enlargement, 110
nodular grow, 111
nuclear palisading, 112
oxyphilic cells, 111
parenchymal mass, 110
primary clear cell hyperplasia, 113–114
PTH, 109
secondary
chief cells, 116
diffuse hyperplasia, 117
fibrosis and fibrous bands, 117
foci of amyloid, 118
hemosiderin deposition, 117
nodular growth, 115
nodular hyperplasia, 115
oxyphilic cells, 116
parathyroid tissue, implant, 118
parenchymal mass, 115
tertiary parathyroid hyperplasia, 118
Parathyroiditis, 106–107
Parathyroid lipoadenoma, 127
Parathyromatosis
calcimimetic agents, 139
features, 140
hypercellular parathyroid tissue, nodules, 140
serum calcium level, 140
Pendred syndrome, 25
Pheochromocytoma
adrenal cortical adenoma, 193
alveolar and trabecular growth patterns, 191
composite, 194

degenerative features, hyalinization and fibrosis, 192
description, 187
epithelioid cells, 190
histologic features, 190
macroscopically cystic lesions, 192
metastasis, skull, 193
mitotic figure, 192
neuroendocrine tumors, 190
nuclear
pleomorphism, 191
pseudoinclusions, 191
paraganglioma, 193
pseudocyst, 193
syndrome-associated tumors, 189
yellow adrenal cortical tissue, 189
"zellballen" growth pattern, 190
Poorly differentiated thyroid carcinoma
external-beam radiotherapy, 67
insular growth pattern, 68
necrosis, 68
operational pathologic definition, 67
relapse-free and cause-specific survival rates, 67
TP53 mutations, 68
Turin criteria, 67
uniform tumor cells, 68
PPNAD. *See* Primary pigmented nodular adrenocortical disease (PPNAD)
Primary pigmented nodular adrenocortical disease (PPNAD)
affected adrenal glands, 162
bilateral micronodular hyperplasia, 162
corticomedullary junction, 163
description, 159
lipofuscin, 163
zona reticularis–type, 163

R
Renal cell carcinoma, 208
Rhabdomyosarcoma, 94
Riedel thyroiditis. *See* Fibrous (Riedel) thyroiditis

S
Schwannoma, 203
Sclerosing mucoepidermoid carcinoma
in adult women, 87
invasive growth recognization, 88
mucous cells, 88
Solid cell nests
oval cells with fine chromatin, 4
PTCs, 4
Solid variant of PTC, 45
Solitary fibrous tumor, 91
Squamous cell carcinoma
adolescent, Hashimoto thyroiditis, 89
keratinization, 89
pure squamous differentiation, 89
Struma ovarii, 9–10
Synovial sarcoma, 93

T
Tall cell variant of PTC, 46
Teratoma, 95, 204
Thyroglossal duct cyst, 9
Thyroid goiter
amyloid, 25, 28–29
Cowden syndrome, 25
dyshormonogenetic goiter, 27–28
endemic, 25
malignancy, 25
medications, 25
meta-analysis, 25
multinodular goiter, 26–27
nontoxic, 25
Pendred syndrome, 25
toxic multinodular, 25
Thyroid histology
calcitonin mRNA, 1
C cells, 1
colloid, 1
ectopic thyroid tissue, 8
immunohistochemical stains, 1
minocycline and amiodarone, 5–6
normal thyroid (*see* Normal thyroid)
palpation thyroiditis, 7
radiation changes, 5
solid cell nests (*see* Solid cell nests)
struma ovarii, 9–10
thyroglossal duct cyst, 9
thyroid needle-biopsy site, 7
TTF1, 1
Thyroiditis
acute inflammation, 13, 14
de Quervain granulomatous, 13, 14–15
fibrous (Riedel), 13, 16
focal lymphocytic, 18
Hashimoto, 13, 17–18
Thyroid needle-biopsy site, 7
Thyroid-stimulating hormone (TSH), 3
Thyroid transcription factor 1 (TTF1), 1, 3, 83, 84
Thyroid tumors
angiosarcoma, 92
CASTLE, 94–95
langerhans cell histiocytosis, 91
low-grade fibromyxoid sarcoma, 93
lymphoma, 90
paraganglioma, 96
rhabdomyosarcoma, 94
sclerosing mucoepidermoid carcinoma, 87–88
solitary fibrous tumor, 91
squamous cell carcinoma, 89
synovial sarcoma, 93
teratoma, 95
TSH. *See* Thyroid-stimulating hormone (TSH)
TTF1. *See* Thyroid transcription factor 1 (TTF1)

U
Unusual adrenal tumors
adenomatoid, 201, 204–205
angiosarcoma (*see* Angiosarcoma)
leiomyosarcoma, 203
malignant melanoma, 201
primary lymphoma, 201
schwannoma, 203
teratoma, 204

W
Warthin-like variant of PTC, 42